Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for GeoVax Labs Inc. (GOVX : NSDQ)
 
 • Company Description   
GeoVax Labs Inc. is a clinical-stage biotechnology company. It engages in developing human vaccines against infectious diseases and cancer using a novel patented Modified Vaccinia Ankara-Virus Like Particle based vaccine platform. GeoVax Labs Inc. is based in ATLANTA, GA.

Number of Employees: 11

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.39 Daily Weekly Monthly
20 Day Moving Average: 3,690,035 shares
Shares Outstanding: 9.45 (millions)
Market Capitalization: $13.13 (millions)
Beta: 1.88
52 Week High: $7.50
52 Week Low: $0.55
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 55.60% 70.38%
12 Week -22.35% -12.73%
Year To Date -61.60% -53.09%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1900 LAKE PARK DRIVE SUITE 380
-
SMYRNA,GA 30080
USA
ph: 678-384-7220
fax: 678-384-7281
investor@geovax.com http://www.geovax.com
 
 • General Corporate Information   
Officers
David A. Dodd - Chief Executive Officer;President
Mark W. Reynolds - Chief Financial Officer
Randal D. Chase - Director
David A. Dodd - Director
Dean G. Kollintzas - Director

Peer Information
GeoVax Labs Inc. (CORR.)
GeoVax Labs Inc. (RSPI)
GeoVax Labs Inc. (CGXP)
GeoVax Labs Inc. (BGEN)
GeoVax Labs Inc. (GTBP)
GeoVax Labs Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 373678507
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/10/22
Share - Related Items
Shares Outstanding: 9.45
Most Recent Split Date: 9.00 (0.05:1)
Beta: 1.88
Market Capitalization: $13.13 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/10/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.16
Price/Cash Flow: -
Price / Sales: 36.79
EPS Growth
vs. Year Ago Period: -17.24%
vs. Previous Quarter: 84.82%
Sales Growth
vs. Year Ago Period: -25.45%
vs. Previous Quarter: -50.30%
ROE
03/31/22 - -146.19
12/31/21 - -119.05
09/30/21 - -36.51
ROA
03/31/22 - -116.36
12/31/21 - -104.52
09/30/21 - -35.39
Current Ratio
03/31/22 - 4.75
12/31/21 - 2.14
09/30/21 - 54.05
Quick Ratio
03/31/22 - 4.75
12/31/21 - 2.14
09/30/21 - 54.05
Operating Margin
03/31/22 - -5,443.98
12/31/21 - -4,823.64
09/30/21 - -1,305.93
Net Margin
03/31/22 - -5,443.98
12/31/21 - -4,823.64
09/30/21 - -1,305.93
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 1.20
12/31/21 - 0.68
09/30/21 - 2.85
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©